How to Get Compounded BPC-157 Once FDA Adds It to the 503A List

Once BPC-157 appears on the FDA’s 503A bulks list, any state-licensed 503A pharmacy may compound the peptide for an identified individual patient who holds a valid prescription. Getting it will involve three steps: (1) work with a U.S. prescriber willing to write a patient-specific BPC-157 prescription, (2) send that prescription to a 503A pharmacy that stocks FDA-registered BPC-157 active pharmaceutical ingredient, and (3) verify that the finished vial meets quality and storage standards before you use it. The process is similar to how compounded semaglutide is dispensed today, but the 503A listing removes the legal gray area that currently limits access.

• The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed BPC-157 on July 23 2026 for potential inclusion on the 503A bulks list.(fda.gov)
• 503A pharmacies may only compound a bulk substance on the list for an individual patient with a prescription that names that patient.(fda.gov)
• Early phase 1 data in 32 healthy volunteers found oral BPC-157 up to 9 mg per day for two weeks was well tolerated with no serious adverse events reported.(pmc.ncbi.nlm.nih.gov)
• Common formulations will likely be 200–500 mcg/mL bacteriostatic saline vials, but stability testing is required before a pharmacy can assign beyond-use dates.(pmc.ncbi.nlm.nih.gov)
• Contact your healthcare provider immediately if you develop unexplained swelling, rash, or shortness of breath after any injectable peptide.

What BPC-157 Is and Why the 503A List Matters

BPC-157 is a 15-amino-acid synthetic fragment of gastric protein BPC that shows anti-inflammatory and tissue-healing effects in animal studies. It is not FDA-approved for any indication, so it can only be supplied through compounding or research channels. The 503A bulks list is the agency’s official roster of bulk drug substances that 503A pharmacies may use when compounding for human patients who need a custom medication and when no FDA-approved product already exists.(fda.gov)

Why the listing changes everything: Before a substance is listed, pharmacies that compound it risk FDA enforcement for using a non-approved bulk ingredient. A listing signals that the agency has reviewed available safety data and decided the substance can be compounded under Section 503A when a prescriber determines a clinical need.(fda.gov)

For background on peptide access, see our comprehensive peptide prescription guide and our detailed explanation of online peptide visits.

Key FDA Milestones Leading to Access

The road to legal compounding involves nomination, review, and rule-making. The table below tracks the major public dates so far and what could happen next.

*Dates marked with an asterisk are projections based on the average 12- to 18-month gap between PCAC vote and final rule for past peptides such as semaglutide.

Step-by-Step Guide to Getting a Prescription

You will need a licensed U.S. prescriber who feels BPC-157 is medically appropriate for you. Because the peptide remains investigational, many clinicians will wait for more data. Here is the practical workflow:

1. Confirm clinical rationale: Discuss your specific injury or condition (for example, tendon strain or inflammatory bowel flare) and what conventional therapies you have tried.

2. Obtain informed consent: The prescriber should document that BPC-157 is not FDA-approved, that human data are limited (only phase 1 safety and small pilot studies exist), and that potential risks include immunogenic reactions and unknown long-term effects.(fda.gov)

3. Generate a patient-specific prescription: Section 503A requires the prescription to list your name, address, and the exact formulation (e.g., “BPC-157 500 mcg/mL in 6 mL multi-dose vial; inject 200 mcg subcutaneously daily for four weeks”).(fda.gov)

4. Select a qualified pharmacy: See next section for vetting tips.

5. Verify shipment and dispense: The pharmacy must label the vial with the beyond-use date (BUD), lot number, storage instructions, and your name. Federal law prohibits compounding “for office use” or mass sales outside patient prescriptions, so avoid suppliers offering bulk kits without paperwork.

For practical dosing considerations, bookmark our BPC-157 dosage guide.

How to Choose a 503A Pharmacy

Not all compounding pharmacies are created equal. Use this checklist before sending your prescription:

Office-use prohibition: Under FDA guidance, Section 503A pharmacies may not compound BPC-157 for physician office stock. Each vial must be tied to a named patient.(fda.gov)

How to Store and Use Compounded BPC-157 Safely

Proper storage maintains potency and reduces infection risk. We cover logistics in depth in our storage guide, but key points include:

Refrigeration: Most pharmacies assign a 2 °C–8 °C BUD of 28 days based on peptide degradation kinetics. Do not freeze unless the pharmacy explicitly validates stability.

Needle hygiene: Use a new insulin syringe for every injection and wipe the vial septum with 70% isopropyl alcohol.

Dose measurement: If your pharmacy supplies 200 mcg/mL, a 0.10 mL pull equals 20 mcg. Our absorption guide explains why subcutaneous belly fat is the most common site.